10-K/A: Allurion Restates Financials Amidst Material Weaknesses

Allurion Technologies, Inc. restates prior financial statements due to material weaknesses in internal controls, reporting a reduced net loss for 2024 but facing ongoing liquidity concerns and NYSE compliance challenges.

Summary

• Allurion Technologies, Inc. (ALUR) filed an amended Annual Report on Form 10-K/A to restate previously issued consolidated financial statements for the fiscal years ended December 31, 2023 and 2024, and quarterly reports for Q1, Q2, Q3 2024 and Q1 2025.
• The restatement was triggered by an error identified during the preparation of Q2 2025 financials, leading to overstatements and understatements in Other comprehensive income (loss), Other income (expense), Net income (loss), Accumulated other comprehensive income (loss), and Accumulated deficit.
• The error stemmed from existing material weaknesses related to insufficient staff with public company and technical accounting experience, and inadequate control activities and risk assessment.
• The restatement had no impact on revenue, gross profit, operating expenses, operating profit (loss), or cash and cash equivalents.
• Management concluded that internal control over financial reporting was not effective as of December 31, 2024 and 2023, and disclosure controls and procedures were not effective as of December 31, 2024.
• The company reported a net loss of $7.2 million for the year ended December 31, 2024, a significant improvement from the $82.8 million net loss in 2023 (both restated figures).
• Revenue decreased by 40% to $32.1 million in 2024 from $53.5 million in 2023, attributed to lower re-order rates, macroeconomic headwinds, and a $1.2 million reduction from customer returns in France due to a temporary sales suspension.
• Operating expenses decreased across sales and marketing, R&D, and general & administrative categories in 2024, reflecting cost reduction initiatives including a workforce reduction of approximately 50% (113 roles).
• The company announced topline results from its AUDACITY pivotal trial, achieving the responder rate co-primary endpoint (58% of subjects lost >5% total body weight at 48 weeks) but missing the comparative co-primary endpoint (2.69% superiority margin vs. pre-specified 3%).
• The AUDACITY trial reported a serious adverse event rate of 3.1%, noted as the lowest for a liquid-filled intragastric balloon in an FDA pivotal trial.
• Sales of the Allurion Balloon in France resumed on February 13, 2025, after the French regulatory authority (ANSM) repealed its temporary suspension following a remediation plan.
• Initial results from a combination therapy trial of the Allurion Program with low-dose GLP-1 showed average total body weight loss of 20.3% and a 15% increase in lean body mass after 8 months, with 100% GLP-1 adherence.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and potential non-compliance with financial covenants.
• Allurion is not in compliance with NYSE's minimum market capitalization standard and is subject to a cure period, though it regained compliance with the minimum bid price standard after a 1-for-25 reverse stock split in January 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financial statements, identified material weaknesses in internal controls, and the explicit 'going concern' warning. While there are positive clinical trial results and recent capital raises, these appear to be survival-driven rather than indicative of strong, sustainable growth, especially given the significant revenue decline and ongoing NYSE compliance issues. The missed FDA trial endpoint, even if minor, adds to the uncertainty.

Positives

• Net loss significantly decreased to $7.2 million in 2024 from $82.8 million in 2023 (restated figures), indicating improved financial performance despite ongoing losses.
• Operating expenses were substantially reduced across sales and marketing (-45%), R&D (-37%), and general and administrative (-38%) in 2024, reflecting successful cost reduction initiatives.
• The AUDACITY pivotal trial achieved its responder rate co-primary endpoint, with 58% of Allurion Balloon subjects losing more than 5% of their total body weight at 48 weeks.
• The AUDACITY trial reported a low serious adverse event rate of 3.1%, which is the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon.
• Sales of the Allurion Balloon in France have successfully resumed as of February 13, 2025, following the completion of a remediation plan with the French regulatory authority (ANSM).
• Initial data on the combination of the Allurion Program with low-dose GLP-1 therapy showed promising results: 20.3% average total body weight loss, 15% increase in lean body mass, and 100% GLP-1 adherence over 8 months, potentially addressing GLP-1 side effects like muscle wasting and adherence issues.
• The company successfully raised capital through multiple offerings in January and February 2025, including $2.5 million from RTW, $7.4 million from a public offering and private placement, and $4.7 million from another public offering and private placement, plus $1.4 million from Leavitt.
• Regained compliance with NYSE's minimum bid price standard after a 1-for-25 reverse stock split in January 2025.

Negatives

• Revenue decreased by 40% to $32.1 million in 2024 from $53.5 million in 2023, indicating a significant decline in sales volume and re-order rates.
• The AUDACITY pivotal trial missed its comparative co-primary endpoint, with a 2.69% superiority margin in total body weight loss compared to the pre-specified 3% margin.
• The company continues to incur significant net operating losses and expects to do so for the foreseeable future, with an accumulated deficit of $222.2 million as of December 31, 2024.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least one year from the financial statement issuance date.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024 and 2023, primarily due to insufficient staff with public company and technical accounting experience and inadequate control activities.
• The company is not in compliance with the NYSE's minimum market capitalization standard ($50.0 million) and is under a cure period, risking potential delisting.
• The restatement of previously issued financial statements for multiple periods may lead to additional risks, including unanticipated costs, legal proceedings, regulatory actions, and adverse effects on investor confidence and share price.

Risks

• Inability to achieve and maintain profitability due to reliance on Allurion Balloon sales and potential failure to gain market acceptance.
• Difficulties associated with a limited operating history in competitive and rapidly evolving markets, including challenges in expanding sales force, increasing brand awareness, and managing growth.
• Dependence on patients' willingness to pay out-of-pocket for treatments, as third-party reimbursement is not expected, making the company vulnerable to adverse economic conditions.
• Potential negative impact on business if competitors develop safer, more effective, or easier-to-use products, including weight loss drugs like GLP-1s and compounded drugs.
• Uncertainty in obtaining and maintaining regulatory approvals or clearances for current and future products in the U.S. and international jurisdictions, including potential delays or denials from the FDA.
• Ongoing regulatory obligations and review post-approval, which may result in significant additional expense or penalties for non-compliance.
• Risk of adverse events or undesirable side effects from products leading to withdrawal or modification of regulatory approvals, reputational harm, and product liability claims.
• Vulnerability to supply shortages and price fluctuations due to reliance on a limited number of single-source suppliers for critical components.
• Potential for substantial warranty or product liability claims and other litigation in the ordinary course of business.
• Challenges in attracting and retaining highly skilled employees, particularly in medical device design and sales, and potential disruption from changes in senior management.
• Risks associated with international operations, including compliance with diverse regulatory requirements, political and economic instability, and difficulties in managing global logistics and distribution.
• Exposure to legal or regulatory action or claims if the company fails to comply with evolving healthcare regulations, including anti-kickback laws, false claims laws, and privacy regulations (e.g., HIPAA, GDPR).
• Risks related to the AllurionMeds program, which offers compounded semaglutide, due to increased scrutiny by the FDA and state agencies, potential supply limitations, and intellectual property challenges.
• Cybersecurity threats, system failures, or security breaches affecting internal computer systems or third-party providers, potentially leading to data loss, litigation, and reputational harm.
• Uncertainty regarding the value and enforceability of intellectual property rights, including potential patent litigation, challenges to patent validity, and inability to protect trade secrets.
• Significant amount of debt and financial covenants that may restrict business operations and ability to secure additional financing.
• Potential for substantial dilution of existing stockholders' ownership from future equity sales, including through the Chardan Equity Facility and warrant exercises.
• Volatility in share price due to various market and industry factors, including the impact of restated financials and material weaknesses in internal controls.
• Risk of delisting from the NYSE if the company fails to meet continued listing standards, particularly the minimum market capitalization standard.

Future Outlook

The company plans to submit the fourth and final module of the premarket approval application (PMA) to the FDA based on the AUDACITY trial results. It intends to explore the combination of the Allurion Program with GLP-1 receptor agonists in future clinical trials to further validate effects on weight loss, muscle mass, and GLP-1 adherence. The company aims to deepen its global presence, launch the Allurion Program in new markets including the U.S., and achieve profitability by implementing operational efficiency initiatives and re-allocating sales and marketing investment. It expects sales and marketing, and R&D costs to decrease in 2025 due to cost reduction initiatives and the nearing completion of the AUDACITY trial. The company anticipates transitioning to compliance with the ISO 27001:2022 version of the information security standard prior to the required transition date of April 30, 2025.

Management Comments

• Management believes the Allurion Program is synergistic in combination with other weight loss therapies, including GLP-1 receptor agonists.
• Management believes the proprietary technologies differentiating the Allurion Balloon enable improved safety and efficacy outcomes.
• Management believes the VCS can potentially be a platform for optimal long-term follow-up after other medical and surgical weight loss interventions in the future.
• Management believes initial data suggests that a combination approach could address the challenges of GLP-1s, including muscle wasting and lack of adherence.
• Management believes the Allurion Program is significantly more affordable for patients than alternatives while maintaining attractive health care provider economics.
• Management believes that by combining with the Allurion Program, GLP-1 dosage can be lowered, which can substantially decrease the cost of GLP-1 therapy.
• Management believes the Allurion Program can be delivered by a much wider group of health care providers across multiple specialties.
• Management believes the broad intellectual property portfolio, combined with proprietary manufacturing processes and regulatory approvals, provides a strong market position.
• Management believes the in-house production team's manufacturing experience, know-how, and process-related trade secrets are a competitive advantage.
• Management believes the current facilities will give adequate manufacturing capacity to meet demand for at least the next two years.
• Management believes that the measures taken and being taken to remediate material weaknesses will be effective.

Industry Context

The global obesity treatment market is projected to reach $54 billion by 2030, driven by rising obesity rates worldwide. Allurion operates in a highly competitive and rapidly changing industry, competing with traditional lifestyle modifications, pharmaceutical therapies (especially GLP-1 receptor agonists like those from Novo Nordisk and Eli Lilly), bariatric surgery, and other intragastric balloon manufacturers (e.g., Boston Scientific, ReShape Lifesciences, Spatz FGIA Inc.). Allurion differentiates itself with a 'Procedureless' swallowable balloon and an AI-powered virtual care suite, aiming to address limitations of existing treatments such as invasiveness, high cost, muscle wasting (with GLP-1s), and poor adherence. The company's focus on combination therapy with low-dose GLP-1s positions it to potentially mitigate some of the known drawbacks of GLP-1s alone, such as muscle loss and adherence issues, which are significant concerns in the broader pharmaceutical obesity market.

Comparison to Industry Standards

• The Allurion Balloon's AUDACITY trial reported a serious adverse event (SAE) rate of 3.1%, which is stated as the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon. This compares favorably to ReShape Lifesciences, Inc.'s ReShape Integrated Duo Balloon System (approx. 7.5% SAE rate) and Apollo Endosurgery, Inc.'s ORBERA Intragastric Balloon System (approx. 10% SAE rate).
• Intolerance rates for endoscopic balloons (ReShape Duo Balloon and ORBERA Balloon) were approximately 14-17%, significantly higher than the Allurion Balloon's approximate 1-3% intolerance rate.
• The Allurion Program's average weight loss of 14% of total body weight over four months and 95-96% maintenance at one year compares favorably to ReShape's pivotal trial, where mean weight loss at 24 weeks was 14.3 pounds, and 40% of that weight loss was regained by 48 weeks, resulting in a mean weight loss of 9.9 pounds.
• The Allurion Program's ability to preserve or increase muscle mass (e.g., 5.6% gain in lean body mass in one study) contrasts with previous studies on GLP-1 therapy, which demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.
• The combination of the Allurion Program with low-dose GLP-1s showed 20.3% average total body weight loss and a 15% increase in lean body mass, and 100% GLP-1 adherence through 8 months, potentially addressing the 30% discontinuation rate within the first month and 58% discontinuation rate before clinically meaningful benefit for GLP-1s alone.
• The 'Procedureless' nature of the Allurion Balloon (no surgery, endoscopy, or anesthesia for placement) offers a significant advantage over competitors like Boston Scientific Corporation, ReShape Lifesciences, Inc., and Spatz FGIA Inc., whose FDA-approved balloons all require endoscopy and anesthesia for placement and/or removal, leading to lower cost and inconvenience for patients.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• The company faces inherent risk of product liability exposure related to the sale of the Allurion Balloon and products in clinical trials, which could lead to costly litigation.
• The restatement of financial statements may lead to additional legal proceedings, including securities class action lawsuits, stockholder derivative suits, and enforcement actions by regulatory authorities like the SEC and NYSE.

Related Party Transactions

• Certain PIPE Investors, including directors Michael Davin ($1,233 shares) and Omar Ishrak ($28,410 shares), and RTW ($85,230 shares), subscribed for shares in connection with a private placement for an aggregate of $37.9 million.
• The Shantanu K. Gaur Revocable Trust of 2021 (affiliated with CEO Shantanu Gaur) contributed 3,170 shares of common stock as capital contribution.
• Krishna Gupta (director) forfeited 3,170 restricted stock units via an RSU Forfeiture Agreement.
• Hunter Ventures Limited (HVL), affiliated with director Krishna Gupta, was involved in a $13 million convertible bridge note and subsequent termination agreement, leading to the issuance of 15,508 shares of common stock to HVL.
• RTW (a significant investor with director nomination rights) received $40.0 million in Revenue Interest Financing and an additional $7.5 million via a PIPE Conversion Option exercise, obligating future revenue interest payments.
• RTW also purchased $48.0 million in convertible senior secured notes from the company in April 2024.
• RTW participated in the July 2024 Public Offering, purchasing 9,594 shares of common stock and warrants for approximately $0.3 million.
• RTW purchased 2,260,159 shares of Series A Preferred Stock (converted to 90,407 common shares) and 90,407 private placement warrants for approximately $2.7 million in July 2024.
• In January 2025, RTW purchased 841,751 shares of common stock for approximately $2.5 million.
• Leavitt Equity Partners LLC (Leavitt), an accredited investor, purchased 267,686 shares of common stock and 535,372 common warrants for approximately $1.4 million in February 2025.
• The company had consulting agreements with KKG Enterprises, LLC and Remus Group Management, LLC (both affiliated with director Krishna Gupta) in Q1 2023 for advisory services, totaling $0.5 million in payments, which were terminated in June 2023.
• Allurion Middle East Medical Instruments Trading, LLC, a UAE subsidiary, has a 51% majority owner (Shuraa Management & Consultancy LLC) as required by UAE law, with profits distributed 20% to Shuraa and 80% to Allurion. It also had lease agreements with an affiliate of Shuraa.
• The company had a corporate officer agreement with Benoit Chardon (former Chief Commercial Officer) and his solely-owned entity, Benoit Chardon Consulting (BCC), which was terminated in December 2023 with a lump-sum termination fee of $0.2 million.
• The company had a lease agreement for office space in Paris with LNMP JPBC Investment, partially owned by Benoit Chardon, which was terminated in February 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises and warrant exercises. The restatement and material weaknesses may erode investor confidence and negatively impact share price. The 'going concern' warning indicates substantial risk to investment value. NYSE delisting risk could further reduce liquidity and market price.
• **Employees:** Experienced significant workforce reductions (approx. 50% in November 2024), leading to potential morale issues and attrition. The company's ability to attract and retain skilled personnel may be impacted by financial instability and stock price volatility.
• **Customers (Health Care Providers):** May face uncertainty regarding product supply if manufacturing capabilities cannot keep up with demand or if supplier relationships are disrupted. The company's ability to provide consistent support and education may be affected by internal operational changes. Resumption of sales in France is positive for French providers.
• **Patients:** Benefit from the Allurion Program's 'Procedureless' nature and promising combination therapy results with GLP-1s. However, potential product misuse due to inadequate provider training or adverse events could lead to dissatisfaction. The long-term availability of the AllurionMeds program is uncertain due to regulatory scrutiny on compounded semaglutide.
• **Suppliers:** The company's reliance on a limited number of single-source suppliers creates risk for both parties if supply is interrupted or if the company faces financial difficulties affecting payments.
• **Creditors (RTW, other lenders):** The company has significant debt obligations and financial covenants. The 'going concern' warning and potential non-compliance with covenants pose a risk to creditors, although RTW has recently provided additional financing and holds substantial collateral.

Next Steps

• Submit the fourth and final module of the premarket approval application (PMA) to the FDA for the Allurion Balloon.
• Perform prospective clinical trials on the combination of the Allurion Balloon and low-dose GLP-1s to further validate effects on weight loss, muscle mass, and GLP-1 adherence.
• Continue to implement operational efficiency initiatives to accelerate the path to profitability.
• Invest strategically in existing markets and leverage commercial strategies to drive procedure and revenue growth.
• Expand the customer base in existing or new target markets.
• Obtain timely regulatory approvals and maintain existing ones for products in new and existing markets.
• Improve and increase performance in the sales and marketing organization, and expand international programs.
• Transition to compliance with the ISO 27001:2022 version of the information security standard prior to April 30, 2025.
• Remediate identified material weaknesses in internal control over financial reporting by hiring additional accounting staff, implementing a new ERP system, and adding review controls.
• Seek stockholder approval for the issuance of shares of common stock underlying the January and February 2025 common warrants at a special meeting scheduled for April 4, 2025.
• Continue efforts to regain compliance with the NYSE's Minimum Market Capitalization Standard within the 18-month cure period.

Key Dates

Recommendation

The filing reveals severe underlying issues that outweigh any positive developments. The explicit 'going concern' warning, coupled with the restatement of financials due to 'material weaknesses' in internal controls and 'lack of sufficient levels of staff with public company and technical accounting experience,' indicates fundamental flaws in financial management and reporting. The 40% revenue decline is alarming, suggesting significant business contraction. While recent capital raises provide short-term liquidity, they are dilutive and appear to be for survival rather than robust growth. The missed FDA trial endpoint, even if minor, adds regulatory uncertainty. The NYSE non-compliance for market capitalization further highlights the precarious position. These factors collectively point to a high-risk investment with significant downside potential, making a 'strong sell' recommendation appropriate for a seasoned investor.

Keywords

Weight Loss, Medical Device, Intragastric Balloon, Allurion Program, FDA Approval, SEC Restatement, Internal Controls, Going Concern, GLP-1, Obesity Management, Financial Reporting, Corporate Governance, Clinical Trials, Capital Raise, NYSE Listing